Sign In
Buy KURA
$8.66
-0.315 (-3.51%)
At Close: Jun 03, 2026
Kura Oncology: A Cautious Buy
08:08am, Thursday, 04'th Dec 2025
Kura Oncology (KURA) is rated a cautious Speculative Buy, driven by Komzifti's FDA approval and frontline AML potential. KURA's near-term revenue under the current label is meaningful but insufficient
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, toda
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data
06:36pm, Tuesday, 02'nd Dec 2025
Kura Oncology remains a Strong Buy, driven by Ziftomenib's differentiated safety profile and significant AML market potential. KURA's Ziftomenib avoids a QTc prolongation boxed warning, offering a pot
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
05:16pm, Tuesday, 25'th Nov 2025
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United States KOMZIFTI, the first and only once-daily FDA-approved m
AXQ Capital LP Raises Stock Position in Kura Oncology, Inc. $KURA
03:34am, Tuesday, 25'th Nov 2025
AXQ Capital LP boosted its stake in shares of Kura Oncology, Inc. (NASDAQ: KURA) by 74.2% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 45,472 shares of t
Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript
05:23pm, Wednesday, 19'th Nov 2025
Kura Oncology, Inc. ( KURA ) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia November 13, 2025 12:30 PM EST Company Participants Greg Mann Troy Wilson
Kura Oncology (NASDAQ:KURA) Sees Strong Trading Volume on Analyst Upgrade
02:40am, Saturday, 15'th Nov 2025
Shares of Kura Oncology, Inc. (NASDAQ: KURA - Get Free Report) saw strong trading volume on Friday after UBS Group raised their price target on the stock from $14.00 to $16.00. UBS Group currently has
Acadian Asset Management LLC Boosts Stock Holdings in Kura Oncology, Inc. $KURA
03:15am, Friday, 14'th Nov 2025
Acadian Asset Management LLC raised its holdings in Kura Oncology, Inc. (NASDAQ: KURA) by 163.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange
– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low surviv
US FDA approves Kura Oncology's blood cancer therapy
10:32am, Thursday, 13'th Nov 2025
The U.S. Food and Drug Administration has approved Kura Oncology's drug to treat a rare form of blood cancer that has returned or resisted initial therapy, the regulator said on Thursday.
Kura Oncology to Participate in Upcoming Investor Conference
04:05pm, Wednesday, 12'th Nov 2025
SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 07'th Nov 2025
SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicine
Kura Oncology, Inc. (KURA) Q3 2025 Earnings Call Transcript
03:46pm, Tuesday, 04'th Nov 2025
Kura Oncology, Inc. ( KURA ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Greg Mann Thomas Doyle - Senior Vice President of Finance & Accounting Troy Wilson - Chairman, CEO
Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates
08:46am, Tuesday, 04'th Nov 2025
Kura Oncology (KURA) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.63 per share a year ago.
